Originally published as JCO Early Release 10.1200/JCO.2007.14.6597 on September 2 2008

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bartlett, J. M.S. Articles by Twelves, C. J. Search for Related Content PubMed PubMed Citation Articles by Bartlett, J. M.S. Articles by Twelves, C. J. Related Articles Related Editorial Social Bookmarking                            What's this?

Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial

John M.S. Bartlett, Alison Munro, David A. Cameron, Jeremy Thomas, Robin Prescott, Chris J. Twelves

From the Endocrine Cancer Research Group, Cancer Research United Kingdom Building, Western General Hospital; Western General Hospital; Medical Statistics Unit, Public Health Services, Medical School, Edinburgh; and the Cancer Research United Kingdom Clinical Centre, St James’ University Hospital, Leeds, United Kingdom

Corresponding author: John M.S. Bartlett, BSc, PhD, FRCPath, Endocrine Cancer Group, Edinburgh Cancer Research Centre, Western General Hospital, Crewe Rd South, Edinburgh, EH4 2XR; e-mail: John.Bartlett{at}ed.ac.uk

Purpose Patients with early breast cancer who receive anthracycline-containing chemotherapy experience improved relapse-free (RFS) and overall survival (OS) compared with those who receive non–anthracycline-containing chemotherapy. Such benefit, however, may be restricted to women whose tumors have specific molecular characteristics. We tested the hypothesis that HER2, epidermal growth factor receptor (EGFr)/HER1, HER3, Ki67, and topoisomerase II expression are predictive of outcome after anthracycline-based chemotherapy.

Methods Tissue microarrays from 322 of 374 women in the BR9601 trial, which compared cyclophosphamide, methotrexate, and fluorouracil (CMF) with epirubicin followed by CMF (epi-CMF), were analyzed for HER1, 2, 3, 4; Ki67; and topoisomerase II protein expression and for HER2/topoisomerase II gene amplification. Their relationships to RFS and OS were investigated, and multiple regression analysis was used to identify interactions.

Results A significant interaction was seen between tumors with normal HER1, HER2 fluorescent in situ hybridization (FISH), or HER3 levels and the enhanced benefit from epi-CMF versus CMF for RFS (hazard ratio [HR], 0.36; HR for overexpressed HER1 or HER2 FISH or HER3, 0.92; P = .035) and for OS (HR, 0.30; HR for overexpressed HER1 or HER2 FISH or HER3), 0.98; P = .023). Neither Ki67 nor TII expressions or gene alterations showed clear predictive value for benefit from the addition of the anthracycline.

Conclusion Patients with HER2 amplified and those with HER1, HER2 FISH, or HER3-positive tumors did not benefit from the addition of epirubicin to CMF. Conversely, patients with HER2 nonamplified and HER1 through HER3–negative tumors showed significantly increased RFS and OS rates when treated with epi-CMF compared with CMF.

published online ahead of print at www.jco.org on September 2, 2008

Supporting in part by educational grant from Pharmacia and by Grant No. A7602/7215 from Cancer Research United Kingdom.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• Anthracyclines: The First Generation of Cytotoxic Targeted Agents? A Possible Dream
  Angelo Di Leo and Erica Moretti
  JCO 2008 26: 5011-5013 [Full Text]

This article has been cited by other articles:

				J.M.S. Bartlett, F. M. Campbell, M. Ibrahim, P. Wencyk, I. Ellis, E. Kay, Y. Connolly, A. O'Grady, S. Di Palma, J. Starczynski, et al. Chromogenic In Situ Hybridization: A Multicenter Study Comparing Silver In Situ Hybridization With FISH Am J Clin Pathol, October 1, 2009; 132(4): 514 - 520. [Abstract] [Full Text] [PDF]

				K. I. Pritchard Commentary: Anthracyclines in Early-Stage Breast Cancer: Is It the End of an Era? Oncologist, October 1, 2009; 14(10): 959 - 962. [Full Text] [PDF]

				R. Tubbs, W. E. Barlow, G. T. Budd, E. Swain, P. Porter, A. Gown, I-T. Yeh, G. Sledge, C. Shapiro, J. Ingle, et al. Outcome of Patients With Early-Stage Breast Cancer Treated With Doxorubicin-Based Adjuvant Chemotherapy As a Function of HER2 and TOP2A Status J. Clin. Oncol., August 20, 2009; 27(24): 3881 - 3886. [Abstract] [Full Text] [PDF]

				K. I. Pritchard Are HER2 and TOP2A Useful As Prognostic or Predictive Biomarkers for Anthracycline-Based Adjuvant Chemotherapy for Breast Cancer? J. Clin. Oncol., August 20, 2009; 27(24): 3875 - 3876. [Full Text] [PDF]

				F. J. Esteva and G. N. Hortobagyi Topoisomerase II{alpha} Amplification and Anthracycline-Based Chemotherapy: The Jury Is Still Out J. Clin. Oncol., July 20, 2009; 27(21): 3416 - 3417. [Full Text] [PDF]

				D. J. Slamon and M. F. Press Alterations in the TOP2A and HER2 Genes: Association With Adjuvant Anthracycline Sensitivity in Human Breast Cancers J Natl Cancer Inst, May 6, 2009; 101(9): 615 - 618. [Full Text] [PDF]

				L. Gianni and P. Valagussa Anthracyclines and Early Breast Cancer: The End of an Era? J. Clin. Oncol., March 10, 2009; 27(8): 1155 - 1157. [Full Text] [PDF]

				P. G. Morris, H. L. McArthur, C. T. Dang, and C. A. Hudis Selection of Appropriate Patients for Anthracycline Therapy ASCO Educational Book, January 1, 2009; 2009(1): 11 - 18. [Abstract] [Full Text] [PDF]

				A. Di Leo and E. Moretti Anthracyclines: The First Generation of Cytotoxic Targeted Agents? A Possible Dream J. Clin. Oncol., November 1, 2008; 26(31): 5011 - 5013. [Full Text] [PDF]